Results 21 to 30 of about 118,029,410 (206)

Ductal carcinoma in situ of the breast [PDF]

BMJ, 2012
#### Summary points Ductal carcinoma in situ (DCIS) is a preinvasive (also termed non-invasive) breast cancer, where proliferations of malignant ductal epithelial cells remain confined within intact breast ducts (fig 1⇓). DCIS is a precursor lesion that has the potential to transform into an invasive cancer over a timescale that may be a few years or ...
Nicola L P, Barnes, Jane L, Ooi, John R, Yarnold, Nigel J, Bundred   +3 more
openaire   +4 more sources

Additional file 1 of Potential biomarkers of ductal carcinoma in situ progression

, 2020
Additional file 1: Table S1. Comparison between control and pure invasive ductal carcinoma. Differentially expressed genes are in bold. Table S2. Comparison between control and pure ductal carcinoma in situ.
Elaine Stur (507776), José Pulido (303763), Raquel Reis (8444421), Eldamária de Vargas Wolfgramm dos Santos (8444424), Narelle Jesus Parmanhani (8444415), Fernanda Garcia (8444430), Diego Prado Ventorim (8444436), Lidiane Agostini (8444418), Laura Ribeiro (848045), Raquel Dettogni (8444406), René Costa Vieira (8079272), Jéssica Santos (8444433), Iara Santana (8444412), Ana Laus (8444409), Márcia Marques (8105822), Iúri Louro (8444439), Rui Reis (4051576), Lyvia Alves (8444427)   +17 more
core   +1 more source

Epidemiology of Ductal Carcinoma In Situ [PDF]

JNCI Monographs, 2010
Ductal carcinoma in situ (DCIS) is a relatively common diagnosis among women undergoing screening mammography. The greatest increases in DCIS incidence have been in non-comedo subtypes of DCIS that are not associated with subsequent invasive cancer. After a 500% increase in DCIS from 1983 to 2003, the incidence of DCIS declined in women aged 50 years ...
openaire   +2 more sources

Readmissions and complications in breast ductal carcinoma in situ: A retrospective study comparing screen- and non-screen-detected patients

Women's Health, 2020
Objective: Population-wide mammographic screening programs aim to reduce breast cancer mortality. However, a broad view of the harms and benefits of these programs is necessary to favor informed decisions, especially in the earliest stages of the disease.
Julieta Politi, María Sala, Laia Domingo, María Vernet-Tomas, Marta Román, Francesc Macià, Xavier Castells   +6 more
doaj   +1 more source

Adenocarcinoma in situ (ductal type) ex pleomorphic adenoma of the lacrimal gland

American Journal of Ophthalmology Case Reports, 2023
Purpose: To present the clinical and histopathological characteristics of a rare case of ductal carcinoma in situ ex pleomorphic adenoma in the lacrimal gland.
Zainab Fakhril-din, Katalin Kiss, Eva Løbner Lund, Jesper Skovlund Jørgensen, Steffen Heegaard   +4 more
doaj   +1 more source

Ductal Carcinoma In Situ: Pathology

Chirurgia, 2021
Ductal carcinomata in situ (DCIS) are both biologically and morphologically a heterogeneous group of neoplastic intraductal proliferations of the breast tissue, they represent an important precursor lesion for the development of invasive breast carcinoma and their diagnosis increases due to improved imaging.
openaire   +2 more sources

Breast Ductal Carcinoma In Situ [PDF]

International Journal of Surgical Oncology, 2012
Ductal carcinoma in situ (DCIS) of the breast is becoming one of the most important diseases diagnosed in preventive medicine screening. The current age-adjusted incidence rate of DCIS is 32.5 per 100,000 women. For women 50–64 years of age, the incidence is approximately 88 per 100,000. Currently, for every 4 diagnoses of invasive breast cancer, there
Sacchini, Virgilio, Fortunato, Lucio, Cody III, Hiram S., Van Zee, Kimberly J., Cutuli, Bruno, Bonanni, Bernardo   +5 more
openaire   +2 more sources

Supplementary Figure S2 from Whole-Exome Sequencing Analysis of the Progression from Non–Low-Grade Ductal Carcinoma In Situ to Invasive Ductal Carcinoma

, 2020
Supplementary Figure S2 shows the repertoire and number of non-synonymous somatic mutations and mutational signatures in synchronously diagnosed ductal carcinoma in situ and invasive ductal carcinoma of no special type and in pure ductal carcinoma in ...
David N. Brown (6742649), Edaise M. da Silva (14937768), Britta Weigelt (40755), Fresia Pareja (677937), Mahsa Vahdatinia (15022077), Andrea Gazzo (15022074), Rui Bi (196341), Felipe C. Geyer (8769284), Ju Youn Lee (6742645), Jorge S. Reis-Filho (6742726), Hannah Y. Wen (6742657), Lorenzo Ferrando (15022083), James B. Hicks (15022086), Anthe A. Stylianou (15022080), Arnaud Da Cruz Paula (8097278), Pier Selenica (6742648)   +15 more
core   +1 more source

Can Molecular Biomarkers Help Reduce the Overtreatment of DCIS?

Current Oncology, 2023
Ductal carcinoma in situ (DCIS), especially in the era of mammographic screening, is a commonly diagnosed breast tumor. Despite the low breast cancer mortality risk, management with breast conserving surgery (BCS) and radiotherapy (RT) is the prevailing ...
Ezra Hahn, Danielle Rodin, Rinku Sutradhar, Sharon Nofech-Mozes, Sabina Trebinjac, Lawrence Frank Paszat, Eileen Rakovitch   +6 more
doaj   +1 more source

Ductal carcinoma in situ revisited

The Breast, 2000
Since our review appeared in The Breast, further information from randomized studies has become available. The EORTC data have been published and are summarized in Table 1. This was a randomized trial assessing the value of radiotherapy after breast conserving surgery.
J M, Dixon, D L, Page
openaire   +2 more sources